REDWOOD CITY, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the appointment of Ginger L. Graham to its board of directors. Ms. Graham is the former President and CEO of Amylin Pharmaceuticals, Inc.; a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with diabetes and obesity. Prior to Amylin, Ms. Graham served as Group Chairman, Office of the President, for Guidant Corporation, a cardiovascular medical device manufacturer, and held a number of management positions at Eli Lilly and Company, a global pharmaceutical company.
"Ginger brings a wealth of industry leadership experience to Genomic Health's board of directors, with expertise in developing and commercializing successful products for pharmaceutical and medical device companies," said Randy Scott, Ph.D., chairman and CEO of Genomic Health. "Her appointment comes at an opportune time as we continue to expand our commercial efforts outside of the United States and invest in our product pipeline, as part of our mission to make individualized treatment standard practice for all cancer patients."
Ms. Graham received a Bachelor of Science in agricultural economics from
About Oncotype DX(R)
Oncotype DX is the first and only multi-gene expression test commercially
available that has clinical evidence validating its ability to predict the
likelihood of chemotherapy benefit as well as recurrence in early-stage breast
cancer. Additionally, the test report provides quantitative scores for certain
individual genes. Oncotype DX has been extensively evaluated in eleven
clinical studies involving more than 4,000 breast cancer pati
|SOURCE Genomic Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved